DK1440709T3 - Kombinationer, der omfatter cGMP PDE5 inhibitorer - Google Patents
Kombinationer, der omfatter cGMP PDE5 inhibitorerInfo
- Publication number
- DK1440709T3 DK1440709T3 DK04010436T DK04010436T DK1440709T3 DK 1440709 T3 DK1440709 T3 DK 1440709T3 DK 04010436 T DK04010436 T DK 04010436T DK 04010436 T DK04010436 T DK 04010436T DK 1440709 T3 DK1440709 T3 DK 1440709T3
- Authority
- DK
- Denmark
- Prior art keywords
- combinations
- pde5 inhibitors
- cgmp pde5
- cgmp
- inhibitors
- Prior art date
Links
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 title 1
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 229960001233 pregabalin Drugs 0.000 abstract 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924958.3A GB9924958D0 (en) | 1999-10-21 | 1999-10-21 | Treatment of neuropathy |
GB0021520A GB0021520D0 (en) | 2000-09-01 | 2000-09-01 | Treatment of neuropathy |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1440709T3 true DK1440709T3 (da) | 2008-03-17 |
Family
ID=26244947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK04010436T DK1440709T3 (da) | 1999-10-21 | 2000-10-17 | Kombinationer, der omfatter cGMP PDE5 inhibitorer |
Country Status (16)
Country | Link |
---|---|
US (2) | US20030162782A1 (hu) |
EP (2) | EP1129706A3 (hu) |
JP (2) | JP2001122803A (hu) |
KR (1) | KR20010051181A (hu) |
AT (1) | ATE380049T1 (hu) |
AU (1) | AU781550B2 (hu) |
CA (1) | CA2323839C (hu) |
CO (1) | CO5271711A1 (hu) |
CY (1) | CY1107285T1 (hu) |
DE (1) | DE60037347T2 (hu) |
DK (1) | DK1440709T3 (hu) |
ES (1) | ES2295726T3 (hu) |
HU (1) | HUP0004120A3 (hu) |
IL (2) | IL152925A (hu) |
PE (1) | PE20010754A1 (hu) |
PT (1) | PT1440709E (hu) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU5714601A (en) * | 2000-04-19 | 2001-10-30 | Univ Johns Hopkins | Methods for prevention and treatment of gastrointestinal disorders |
FR2809623B1 (fr) * | 2000-06-05 | 2003-09-05 | Sanjuan Benito Arranz | Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives) |
DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
IL160307A0 (en) | 2001-08-31 | 2004-07-25 | Univ Rockefeller | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
GB0129274D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Novel kit |
EP1469852A4 (en) * | 2002-01-04 | 2009-12-02 | Ford Henry Health System | DONORS OF NITROGEN MONOXIDE FOR THE TREATMENT OF DISEASES AND INJURIES |
US7419981B2 (en) | 2002-08-15 | 2008-09-02 | Pfizer Inc. | Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor |
GB0219024D0 (en) * | 2002-08-15 | 2002-09-25 | Pfizer Ltd | Synergistic combinations |
US7659305B2 (en) | 2002-10-31 | 2010-02-09 | Pfizer Inc. | Therapeutic proline derivatives |
ES2341240T3 (es) * | 2002-12-13 | 2010-06-17 | Warner-Lambert Company Llc | Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior. |
US7304174B2 (en) | 2003-04-23 | 2007-12-04 | Japan Tobacco Inc. | CaSR antagonist |
DE10325813B4 (de) * | 2003-06-06 | 2007-12-20 | Universitätsklinikum Freiburg | Prophylaxe und/oder Therapie bei der portalen Hypertonie |
DE602005017135D1 (de) | 2004-03-05 | 2009-11-26 | Nycomed Gmbh | Neue verwendung von pde5-hemmern |
BRPI0611095B8 (pt) | 2005-06-06 | 2021-05-25 | Intracellular Therapies Inc | compostos inibidores de pde1, composição farmacêutica compreendendo-os, usos dos mesmos como inibidores de pde1 para o tratamento de doenças relacionadas, tal como doença de parkinson e deficiência cognitiva, e métodos para produção dos ditos compostos |
WO2007025103A2 (en) * | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
WO2007143705A2 (en) * | 2006-06-06 | 2007-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
ES2411604T3 (es) * | 2006-11-13 | 2013-07-05 | Intra-Cellular Therapies, Inc. | Compuestos orgánicos |
JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 新規使用 |
US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
WO2008131256A1 (en) * | 2007-04-19 | 2008-10-30 | Trinity Laboratories Inc. | Improved treatments for premature ejaculation in humans |
AU2008279447A1 (en) * | 2007-07-19 | 2009-01-29 | Metabolex, Inc. | N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the RUP3 or GPR119 receptor for the treatment of diabetes and metabolic disorders |
MX2010006208A (es) * | 2007-12-06 | 2010-12-21 | Intra Cellular Therapies Inc | Compuestos organicos. |
US8273751B2 (en) * | 2007-12-06 | 2012-09-25 | Takeda Pharmaceutical Company Limited | Organic compounds |
SG171776A1 (en) | 2008-12-06 | 2011-07-28 | Intra Cellular Therapies Inc | Organic compounds |
AU2009322905A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR20110098731A (ko) | 2008-12-06 | 2011-09-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
US8536159B2 (en) | 2008-12-06 | 2013-09-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
MX2011005936A (es) * | 2008-12-06 | 2011-12-16 | Intra Cellular Therapies Inc | Compuestos organicos. |
CN102238873A (zh) | 2008-12-06 | 2011-11-09 | 细胞内治疗公司 | 有机化合物 |
US11464781B2 (en) | 2009-02-25 | 2022-10-11 | Intra-Cellular Therapies, Inc. | PDE1 inhibitors for ophthalmic disorders |
WO2010132127A1 (en) | 2009-05-13 | 2010-11-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
SG178279A1 (en) | 2009-08-05 | 2012-03-29 | Intra Cellular Therapies Inc | Novel regulatory proteins and inhibitors |
ES2497566T3 (es) | 2009-10-01 | 2014-09-23 | Cymabay Therapeutics, Inc. | Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida |
WO2011143607A1 (en) * | 2010-05-14 | 2011-11-17 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
US9763948B2 (en) | 2010-05-31 | 2017-09-19 | Intra-Cellular Therapies, Inc. | PDE1 inhibitory compounds and methods |
EP2575765B1 (en) * | 2010-06-07 | 2018-12-05 | Suda Ltd | Oral spray formulations and methods for administration of sildenafil citrate |
EP2585048B1 (en) | 2010-06-23 | 2018-04-11 | CymaBay Therapeutics, Inc. | Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
EP2717877B1 (en) | 2011-06-10 | 2017-11-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN102276511A (zh) * | 2011-06-20 | 2011-12-14 | 兰州博实生化科技有限责任公司 | 1-叔丁氧羰基-3-碘氮杂环丁烷的合成方法 |
US8449565B2 (en) | 2011-07-21 | 2013-05-28 | Francis Duhay | Approaches to venous occlusion for embolus management |
WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
US9545406B2 (en) | 2013-03-15 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Method of treating a CNS injury with a PDE1 inhibitor |
WO2014151409A1 (en) | 2013-03-15 | 2014-09-25 | Intra-Cellular Therapies, Inc. | Organic compounds |
RU2549459C2 (ru) * | 2013-08-20 | 2015-04-27 | Константин Александрович Корейба | Способ лечения нейропатических трофических язв при синдроме диабетической стопы |
WO2015106032A1 (en) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Products and pharmaceutical compositions |
ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
EP3193878B1 (en) | 2014-09-17 | 2021-01-06 | Intra-Cellular Therapies, Inc. | 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one derivatives as phosphodiesterase 1 (pde1) inhibitors for treating diseases, disorders or injuries of the central nervous system (cns) |
AU2015357498B2 (en) | 2014-12-06 | 2019-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP6608934B2 (ja) | 2014-12-06 | 2019-11-20 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
WO2017172795A1 (en) | 2016-03-28 | 2017-10-05 | Intra-Cellular Therapies, Inc. | Novel compositions and methods |
CN109862896A (zh) | 2016-08-03 | 2019-06-07 | 西玛贝医药公司 | 用于治疗炎症性胃肠疾病或胃肠病症的氧亚甲基芳基化合物 |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
ES2927104T3 (es) | 2016-09-09 | 2022-11-02 | Incyte Corp | Derivados de pirazolopiridina como moduladores de HPK1 y usos de los mismos para el tratamiento del cáncer |
WO2018049152A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
EP3509589B1 (en) | 2016-09-12 | 2021-11-17 | Intra-Cellular Therapies, Inc. | Novel uses |
US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
MX2017016930A (es) * | 2017-12-19 | 2019-06-20 | Malesil Research & Tech Llc | Uso del maleato de sildenafil en el tratamiento de ulceras de pie diabetico. |
EP3746081A4 (en) | 2018-01-31 | 2021-10-27 | Intra-Cellular Therapies, Inc. | INNOVATIVE USES |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
SI3755703T1 (sl) | 2018-02-20 | 2022-11-30 | Incyte Corporation | N-(fenil)-2-(fenil)pirimidin-4-karboksamidni derivati in sorodne spojine kot zaviralci HPK1 za zravljenje raka |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
TW202028207A (zh) | 2018-09-25 | 2020-08-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
EP4010338A1 (en) | 2019-08-06 | 2022-06-15 | Incyte Corporation | Solid forms of an hpk1 inhibitor |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT100905A (pt) * | 1991-09-30 | 1994-02-28 | Eisai Co Ltd | Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem |
IL124969A (en) * | 1995-12-28 | 2002-09-12 | Fujisawa Pharmaceutical Co | History of benzimidazole, processes for their preparation and pharmaceutical preparations containing them |
DK0934061T6 (en) * | 1996-07-24 | 2015-01-26 | Warner Lambert Co | Isobutylgaba and its derivatives for the treatment of pain |
US6127418A (en) * | 1997-08-20 | 2000-10-03 | Warner-Lambert Company | GABA analogs to prevent and treat gastrointestinal damage |
HUP0102543A3 (en) * | 1998-04-20 | 2002-01-28 | Pfizer | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction and medicaments containing them |
US6331171B1 (en) * | 1998-06-04 | 2001-12-18 | Alcon Laboratories, Inc. | Tip for a liquefracture handpiece |
GB9823101D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
GB9823103D0 (en) * | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
CA2347950C (en) * | 1998-10-23 | 2005-05-03 | Pfizer Inc. | Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction |
US6411892B1 (en) * | 2000-07-13 | 2002-06-25 | Global Locate, Inc. | Method and apparatus for locating mobile receivers using a wide area reference network for propagating ephemeris |
US6453237B1 (en) * | 1999-04-23 | 2002-09-17 | Global Locate, Inc. | Method and apparatus for locating and providing services to mobile devices |
IL137429A0 (en) * | 1999-07-28 | 2001-07-24 | Pfizer Prod Inc | Methods and compsitions for treating diseases and conditions of the eye |
ATE341329T1 (de) * | 1999-10-12 | 2006-10-15 | Lilly Icos Llc | Arzneimittel zur behandlung von neuropathien |
US7196660B2 (en) * | 2000-11-17 | 2007-03-27 | Global Locate, Inc | Method and system for determining time in a satellite positioning system |
US6560534B2 (en) * | 2001-06-06 | 2003-05-06 | Global Locate, Inc. | Method and apparatus for distributing satellite tracking information |
-
2000
- 2000-10-16 IL IL152925A patent/IL152925A/en not_active IP Right Cessation
- 2000-10-16 IL IL13907300A patent/IL139073A0/xx unknown
- 2000-10-17 EP EP00309129A patent/EP1129706A3/en not_active Withdrawn
- 2000-10-17 ES ES04010436T patent/ES2295726T3/es not_active Expired - Lifetime
- 2000-10-17 PT PT04010436T patent/PT1440709E/pt unknown
- 2000-10-17 AT AT04010436T patent/ATE380049T1/de not_active IP Right Cessation
- 2000-10-17 DK DK04010436T patent/DK1440709T3/da active
- 2000-10-17 EP EP04010436A patent/EP1440709B1/en not_active Expired - Lifetime
- 2000-10-17 DE DE60037347T patent/DE60037347T2/de not_active Expired - Fee Related
- 2000-10-19 CA CA002323839A patent/CA2323839C/en not_active Expired - Fee Related
- 2000-10-20 AU AU66650/00A patent/AU781550B2/en not_active Withdrawn - After Issue
- 2000-10-20 PE PE2000001133A patent/PE20010754A1/es not_active Application Discontinuation
- 2000-10-20 CO CO00080163A patent/CO5271711A1/es not_active Application Discontinuation
- 2000-10-20 HU HU0004120A patent/HUP0004120A3/hu unknown
- 2000-10-21 KR KR1020000062129A patent/KR20010051181A/ko not_active Application Discontinuation
- 2000-10-23 JP JP2000322510A patent/JP2001122803A/ja active Pending
-
2002
- 2002-07-26 US US10/206,615 patent/US20030162782A1/en not_active Abandoned
- 2002-10-10 JP JP2002297617A patent/JP2003119131A/ja active Pending
-
2003
- 2003-12-10 US US10/731,905 patent/US20040122010A1/en not_active Abandoned
-
2008
- 2008-02-18 CY CY20081100193T patent/CY1107285T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
HU0004120D0 (hu) | 2001-01-29 |
ATE380049T1 (de) | 2007-12-15 |
CA2323839C (en) | 2008-03-18 |
KR20010051181A (ko) | 2001-06-25 |
US20040122010A1 (en) | 2004-06-24 |
US20030162782A1 (en) | 2003-08-28 |
IL152925A (en) | 2010-04-15 |
DE60037347T2 (de) | 2008-11-27 |
EP1440709B1 (en) | 2007-12-05 |
EP1440709A3 (en) | 2004-12-08 |
EP1129706A2 (en) | 2001-09-05 |
IL139073A0 (en) | 2001-11-25 |
PT1440709E (pt) | 2008-02-06 |
ES2295726T3 (es) | 2008-04-16 |
CO5271711A1 (es) | 2003-04-30 |
CY1107285T1 (el) | 2012-11-21 |
EP1129706A3 (en) | 2002-01-02 |
AU781550B2 (en) | 2005-05-26 |
EP1440709A2 (en) | 2004-07-28 |
HUP0004120A3 (en) | 2003-11-28 |
DE60037347D1 (de) | 2008-01-17 |
HUP0004120A2 (hu) | 2002-11-28 |
JP2003119131A (ja) | 2003-04-23 |
JP2001122803A (ja) | 2001-05-08 |
AU6665000A (en) | 2001-04-26 |
PE20010754A1 (es) | 2001-07-18 |
CA2323839A1 (en) | 2001-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1440709T3 (da) | Kombinationer, der omfatter cGMP PDE5 inhibitorer | |
BR0108750A (pt) | Variantes da xilanase que apresentam sensibilidade alterada para inibidores da xilanase | |
GB2379798B (en) | Light emitting diode and method for manufacturing the same | |
PL371515A1 (en) | Hif hydroxylase inhibitors | |
ATE404528T1 (de) | 7,9 substituierte tetracyclinverbindungen | |
ECSP045245A (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados | |
BR0110143A (pt) | Derivados de ácido heptenóico de 2-amino-5,6 halogenado úteis como inibidores de sintase de óxido nìtrico | |
BR0102059B1 (pt) | segmento retentor para conjunto turbilhonador. | |
AU148080S (en) | Spray pump head | |
WO2003024489A3 (en) | Combination of a nsaid and a pde-4 inhibitor | |
HN2002000110A (es) | Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple. | |
AU148079S (en) | Spray pump head | |
BR0307595A (pt) | Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico | |
EP1262556A3 (en) | Antimicrobial peptides and method for identifying and using such peptides | |
TNSN06246A1 (fr) | Nouvelle combinaison d'un agent antiemetique et d'un inhibiteur de l'encephalinase | |
ES2168816T3 (es) | Cemento de inyeccion que contiene inhibidores de la corrosion. | |
TR200705146T1 (tr) | Monoamin Yükselmesinin Engellenmesi | |
MY138266A (en) | Treatment of neuropathy | |
WO2002049635A3 (de) | Verwendung von 5-aminolävulinsäure zur restenose-prophylaxe | |
ATE344041T1 (de) | Kombination eines gelatinasehemmers und eines anti-tumor-agent, und deren verwendung | |
ES1048527Y (es) | Pieza perfeccionada para el laminado de tableros. | |
ES1038279Y (es) | Utensilio para el juego de dados. | |
ES1049152Y (es) | Cañon ligero para armas. | |
RU2001103824A (ru) | Средство для лечения острого мышьяковистого периодонтита | |
ECSP003855A (es) | Inhibidores de fosfodiesterasa-4 8-arilquinolina sustituida |